1. Short title This Act may be cited as the Prostate Cancer Community Assistance, Research and Education Act of 2023 or the PC–CARE Act . 2. Findings Congress finds the following: (1) Prostate cancer is the most commonly diagnosed non-skin cancer and the second leading cause of cancer-related deaths among men in the United States. (2) Over 3,100,000 men in the United States live with a prostate cancer diagnosis and it is estimated that in 2023, 288,300 men will be diagnosed with, and more than 34,700 men will die of, prostate cancer. (3) Men with at least one close relative who has been diagnosed with prostate cancer have twice the risk of having prostate cancer compared to the general population. (4) At least 12 percent of men with metastatic prostate cancer have inherited predispositions to the disease and potentially actionable genomic alterations have been identified in over 90 percent of men with metastatic castration-resistant prostate cancer. (5) Advances in science to identify, test, and treat these men at increased genetic risk of disease are needed. (6) African-American men suffer from a prostate cancer incidence rate that is significantly higher than that of White men and have more than double the prostate cancer mortality rate than that of White men. (7) Research has shown that veterans exposed to herbicides, such as Agent Orange, are at higher risk for and more likely to be diagnosed with aggressive forms of prostate cancer. (8) Screening by a digital rectal examination and a prostate-specific antigen blood test can detect the disease at the earlier, more treatable stages. (9) Men diagnosed with early stage disease have a nearly 100 percent 5-year survival rate but only 30 percent of men survive more than 5 years if diagnosed with prostate cancer after the cancer has metastasized. (10) Early-staged prostate cancer has no symptoms, raising the importance of early detection and screening. (11) The Department of Health and Human Services, the Department of Defense, and the Department of Veterans